Lymphoma, T-Cell, Cutaneous: all 342 studies
Page 1 of 4. Open to participants first (61), then studies with results posted, then the rest; newest registration first within each.
- A Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell LymphomaNot yet recruitingNCT07854639Phase 2
- Topical JAK-Inhibition of Early-Stage CTCLNot yet recruitingNCT07781449Phase 2
- Golidocitinib and Chidamide for Cutaneous T-Cell LymphomaRecruitingNCT07754890Phase 1/2
- A Study of Topical Duvelisib in Participants With Early-stage Mycosis FungoidesNot yet recruitingNCT07714187Phase 1
- Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic MalignanciesNot yet recruitingNCT07710781Not applicable
- Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic LeukemiaNot yet recruitingNCT07682792Phase 2
- Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell LymphomaNot yet recruitingNCT07658924Phase 2
- FLASH Pilot Phase 1 Safety StudyNot yet recruitingNCT07608549Not applicable
- Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica.Not yet recruitingNCT07538960
- Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell LymphomaNot yet recruitingNCT07535710Phase 1/2
- Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaRecruitingNCT07356245Phase 2
- Amping up With PemJAKRecruitingNCT07283822Phase 2
- A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)Not yet recruitingNCT07213882Early Phase 1
- A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological MalignanciesRecruitingNCT07195916Phase 1
- A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin LymphomaRecruitingNCT07192471Phase 1
- Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant MaintenanceNot yet recruitingNCT07178457Phase 3
- Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)RecruitingNCT07047885Phase 1
- Long-term Assessment of Chlormethine Gel in Mycosis FungoidesNot yet recruitingNCT07046663
- CD5 CAR T-Cell Therapy for r/r T-cell LymphomasRecruitingNCT07022964Phase 1/2
- A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological MalignanciesRecruitingNCT06914037Phase 1
- Combating Cancer-Related Fatigue: A Personalized Supportive Care ProgramRecruitingNCT06860880Not applicable
- A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCLRecruitingNCT06854653Phase 2
- JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell LymphomasRecruitingNCT06716658Phase 2
- Q702 for the Treatment of Patients With Hematologic MalignanciesRecruitingNCT06712810Phase 1
- A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIARecruitingNCT06698822Phase 2
- Pilot Study to Characterize the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of CLn® Skin Care Body WashEnrolling by invitationNCT06665490
- Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter StudyNot yet recruitingNCT06651203
- Systemic Therapies in the Treatment of Cutaneous T-cell LymphomaRecruitingNCT06588868
- A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell LymphomaRecruitingNCT06436677
- A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune SystemNot yet recruitingNCT06385522Phase 1
- Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCLRecruitingNCT06382844
- Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center StudyRecruitingNCT06037239Phase 1/2
- Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell LymphomaRecruitingNCT05996185Phase 2
- A Registry for People With T-cell LymphomaRecruitingNCT05978141
- Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell LymphomasRecruitingNCT05956041Phase 2
- A Phase I Trial of SIM1811-03 in Subjects With Advanced TumorsRecruitingNCT05781386Phase 1
- Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray SolutionNot yet recruitingNCT05728879Early Phase 1
- Photopheresis in Early-stage Mycosis FungoidesRecruitingNCT05680558Phase 2
- TreAtments and outComes in paTients With prImary CutAneous LymphomaRecruitingNCT05518851
- MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal PhotochemotherapyRecruitingNCT05333367Not applicable
- L19IL2/L19TNF in Skin Cancer PatientsRecruitingNCT05329792Phase 2
- Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell LymphomaRecruitingNCT05313243Phase 2
- A Study of Bexarotene Combined With Radiotherapy in People With Mycosis FungoidesRecruitingNCT05296304Phase 1
- TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis FungoidesNot yet recruitingNCT05205902Phase 3
- Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell LymphomaRecruitingNCT04930653Phase 2
- Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.RecruitingNCT04904146
- Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/LymphomaRecruitingNCT04848064Phase 1
- Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29RecruitingNCT04670874
- Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous LymphomasNot yet recruitingNCT04520529Not applicable
- Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin LymphomaRecruitingNCT04234048Phase 1
- Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell LymphomaRecruitingNCT04128072Phase 2
- A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell LymphomaRecruitingNCT04045470Not applicable
- Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With MogamulizumabRecruitingNCT04014374
- Characterization of the Microbiome in Cutaneous T Cell LymphomaRecruitingNCT03932279
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingNCT03017820Phase 1
- Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell LymphomaRecruitingNCT03011814Phase 1/2
- Tissue Repository: CTCL Collection ProtocolRecruitingNCT02840747
- Registry of Older Patients With CancerRecruitingNCT01137825
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT01137643
- Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer TreatmentRecruitingNCT01087333
- Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis ResearchRecruitingNCT00177268
- PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell LymphomaCompletedNCT05380635Phase 2Results posted
- Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell MalignanciesCompletedNCT04447027Phase 1Results posted
- Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With AlemtuzumabCompletedNCT04312841Phase 2Results posted
- SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis FungoidesTerminatedNCT03713320Phase 2Results posted
- Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell NeoplasmsCompletedNCT03493451Phase 2Results posted
- Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell LymphomaCompletedNCT03409432Phase 2Results posted
- Mechlorethamine Induced Contact Dermatitis Avoidance StudyCompletedNCT03380026Phase 2Results posted
- A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)CompletedNCT03292406Phase 2Results posted
- Study of Pembrolizumab (MK-3475) in Combination With RomidepsinActive, not recruitingNCT03278782Phase 1/2Results posted
- AFM13 in Relapsed/Refractory Cutaneous LymphomasCompletedNCT03192202Phase 1/2Results posted
- VircapSeq Virus Detection in Sézary SyndromeCompletedNCT02836886Results posted
- Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)CompletedNCT02689453Phase 1Results posted
- Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell LymphomaCompletedNCT02676778Phase 2Results posted
- A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersCompletedNCT02643303Phase 1/2Results posted
- Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell LymphomaCompletedNCT02567656Phase 1Results posted
- FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)CompletedNCT02448381Phase 3Results posted
- Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell LymphomaTerminatedNCT02314247Phase 2Results posted
- Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell LymphomaCompletedNCT02296164Results posted
- Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell LymphomaCompletedNCT02232516Phase 2Results posted
- Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid MalignanciesTerminatedNCT01947140Phase 1/2Results posted
- A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell LymphomaCompletedNCT01871727Phase 3Results posted
- Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01839916Phase 2Results posted
- Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasTerminatedNCT01805037Phase 1/2Results posted
- Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin LymphomaCompletedNCT01800838Phase 1Results posted
- Ipilimumab and Local Radiation for Selected Solid TumorsTerminatedNCT01769222Phase 1Results posted
- Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell LymphomaTerminatedNCT01738594Phase 1Results posted
- Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCLCompletedNCT01728805Phase 3Results posted
- Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid MalignanciesTerminatedNCT01678443Phase 1Results posted
- Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)CompletedNCT01676831Phase 1/2Results posted
- Everolimus in Treating Cutaneous T-cell LymphomaTerminatedNCT01637090Phase 2Results posted
- Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous LymphomaTerminatedNCT01579318Phase 2Results posted
- A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)CompletedNCT01578499Phase 3Results posted
- Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 2Results posted
- Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)CompletedNCT01433731Phase 1Results posted
- Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesCompletedNCT01427881Phase 2Results posted
- Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell TransplantTerminatedNCT01419795Phase 2Results posted
- Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin LymphomaTerminatedNCT01408043Not applicableResults posted
- Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression LevelCompletedNCT01396070Phase 2Results posted
- A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological MalignanciesCompletedNCT01384513Phase 2Results posted